Voices
Yuji Uehara, HER2-Altered NSCLC
Yuji Uehara/X

Yuji Uehara: Presenting RWD on 2nd-Line Therapy for HER2-Altered NSCLC at JLCS25

Yuji Uehara, Medical Oncologist at the National Cancer Center of Japan, shared a post on X:

“Excited to present our real-world data on 2nd-line therapy for HER2-altered NSCLC in Japan at JLCS25 on Nov 8. It’s a true honor to present before my esteemed former boss, Dr. Koichi Goto.

  • Nov 8, 8:30-9:30 AM
  • Tokyo International Forum, G510.”

Yuji Uehara: Presenting RWD on 2nd-Line Therapy for HER2-Altered NSCLC at JLCS25

More posts featuring Yuji Uehara.

cancer JLCS 2025 JLCS25 NSCLC OncoDaily Oncology Yuji Uehara